Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Bumping Estimates After Q4 Results

Go back to Canaccord Genuity Maintains a 'Hold' on AngioDynamics (ANGO); Bumping Estimates After Q4 Results